Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV
Open Access
- 28 October 2022
- journal article
- research article
- Published by African Journals Online (AJOL) in African Health Sciences
- Vol. 22 (3) , 426-435
Abstract
Background: People living with HIV need to use antiretroviral therapy throughout their lives. Objectives: Studies on the efficacy and safety of dual therapy are limited in Turkey. We sought to evaluate the treatment efficacy and side effects among patients who were given a combination of dolutegravir (DTG) and lamivudine (3TC) as a maintenance therapy. Methods: This retrospective, single-centre study included individuals with viral suppression who were older than 18 years of age, living with HIV, switched from a combination antiretroviral therapy regimen to DTG-3TC dual therapy, and followed up for at least 6 months. Results: The study included 63 patients living with HIV. The median age was 42 years (interquartile range (IQR): 36-51 years). The median follow-up under the DTG-3TC regimen was 10.4 months (7.1-16.0 months). In the course of dual therapy, no patients developed any serious adverse effects that would necessitate a therapy switch, but virological blips were seen in two patients. Two patients lost their lives, with one dying from suicide and one dying from respiratory failure associated with the underlying chronic obstructive pulmonary disease. Conclusion: The DTG-3TC dual-therapy regimen is a promising and effective therapy that can be used as a treatment of choice for eligible patients. Keywords: Dolutegravir; lamivudine; dual; antiretroviral therapy; efficacy.Keywords
This publication has 36 references indexed in Scilit:
- HIV protease inhibitors in gut barrier dysfunction and liver injuryCurrent Opinion in Pharmacology, 2014
- Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapyAIDS, 2014
- A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study ResultsHIV Research & Clinical Practice, 2012
- Association of tenofovir exposure with kidney disease risk in HIV infectionAIDS, 2012
- Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agentsAIDS, 2012
- Dolutegravir for the treatment of HIVExpert Opinion on Investigational Drugs, 2012
- Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)AIDS, 2011
- Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week ResultsHIV Research & Clinical Practice, 2011
- Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta)Journal of Orthopaedic Research, 2002
- LamivudineDrugs, 1997